This perspective was first shared in our Weekly View e-newsletter, which summarizes the week’s most significant drug pricing news. To subscribe, click here.
We hope everyone is staying safe amid the public health concerns surrounding the spread of COVID-19. As always, keep washing those hands.
Given the situation, and to prioritize the health and safety of all participants, ICER has decided to convert our March 26 public meeting regarding treatments for sickle cell disease into a virtual meeting, which everyone can register to attend here.
Because we’re now conducting this meeting virtually, we understand we may not be able to have as robust a conversation as we normally would about how to weigh potential other benefits, disadvantages, and contextual considerations in the overall assessment of value of the treatments. Therefore, we’ve decided that our independent appraisal committee (the New England CEPAC) will only be voting on the treatments’ comparative clinical effectiveness and the broader contextual considerations associated with the disease, and they will NOT be voting on the therapies’ overall “value for money.”